Figure 7
Visceral adipose tissue remodeling in PDAC patients does not rely on increased browning of white adipose tissue. (A) Immunoblotting with UCP1 (33 kDa) in visceral adipose tissue of non-cancer patients (n = 5) and PDAC patients (n = 5) (top). Immuoblotting with UCP1 in visceral adipose tissue of a non-cancer patient and a PDAC patient with intrascapular brown adipose tissue from a healthy control mouse as a positive control (n = 2) (bottom). (B) Relative mRNA expression levels of UCP1 in visceral adipose tissue of non-cancer patients (n = 5) and PDAC patients (left). Corresponding serum activin A levels are included in ng/ml. Statistical analysis of relative mRNA expression levels of UCP1 in visceral adipose tissue of non-cancer patients (n = 5) and PDAC patients (n = 8) (right). n.s., not significant. (C) Representative immunofluorescence images of UCP1 expression in visceral adipose tissue from patients with low and high circulating activin A levels included in ng/ml. Nuclei were stained with DAPI. (D) Relative mRNA expression levels of HSL (LIPE) in visceral adipose tissue of non-cancer patients and PDAC patients (left). Corresponding serum activin A levels are included in ng/ml. Statistical analysis of relative mRNA expression levels of LIPE in adipose tissue of non-cancer patients (n = 4) and PDAC patients (n = 8) (right). n.s., not significant. Corresponding serum activin A levels are included in ng/ml.
